Lomustine with anlotinib for resistant small cell lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a combination of two drugs for people with extensive-stage small cell lung cancer that has stopped responding to at least two previous treatments. The goal is to see if this combination can help control the cancer when other options have failed.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You must have small cell lung cancer that has spread (extensive-stage) and has gotten worse after at least two lines of treatment.
- You must have at least one tumor that can be measured by scans.
- You should be in generally good health (able to do light activity) with normal or mildly abnormal organ function.
- You must not have had prior treatment with lomustine, anlotinib, or similar anti-angiogenic drugs.
- You must not have uncontrolled brain metastases, active bleeding, or other serious health problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of benmelstobart (an immunotherapy drug), anlotinib (a targeted therapy that blocks blood vessel growth), chemotherapy, and chest radiation for people with extensive-stage small cell lung cancer (cancer that has spread beyond one lung). The goal is to see if this combination helps shrink tumors and control the disease better than standard care.
This trial tests a combination of the targeted drug bemotuzumab, chemotherapy, and anlotinib (which blocks blood vessel growth) followed by radiation therapy for people with extensive-stage small cell lung cancer who haven't had treatment yet. The goal is to see if this approach helps control the cancer.
This trial studies whether continuing anlotinib after the cancer has progressed can help people with advanced lung cancer. It looks at real-world treatment records to see if this approach keeps the cancer stable longer.
This trial tests different experimental drugs matched to the specific genetic makeup of your small cell lung cancer. The goal is to see if targeting your cancer's particular molecular type can shrink tumors or delay their growth better than standard care.
This trial tests a combination of three drugs (benmelstobart, anlotinib, and chemotherapy) for people with extensive-stage small cell lung cancer who haven't had treatment yet. The goal is to see if this combination can shrink tumors and help patients live longer.
This trial tests a combination of two drugs—irinotecan liposome (a chemotherapy) and anlotinib (a targeted therapy)—as a second treatment for small cell lung cancer that returned quickly after initial chemo. The goal is to see if this combo can work better than standard options.
Hear when a new SCLC, Extensive Stage trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.